# Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.

> **NCT02971696** · PHASE3 · COMPLETED · sponsor: **Ain Shams University** · enrollment: 55 (actual)

## Conditions studied

- HCC

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** Best Supportive care

## Key facts

- **NCT ID:** NCT02971696
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2017-11
- **Final completion:** 2018-01
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2018-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02971696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02971696, "Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02971696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*